Ads
related to: metoprolol vs labetalol for tachycardia syndrome patients- ATTR-CM Treatment
Learn more about a treatment for
ATTR-CM that may help.
- Learn More About ATTR-CM
Discover more information about
ATTR-CM including signs & symptoms.
- Get Started On Treatment
Find information about getting
started on a treatment for ATTR-CM.
- Find Patient Resources
Uncover patient resources including
a doctor discussion guide.
- ATTR-CM Treatment
Search results
Results From The WOW.Com Content Network
Group of pharmaceuticals that are used to suppress abnormally fast rhythms (tachycardias), such as atrial fibrillation, supraventricular tachycardia and ventricular tachycardia. Type I (sodium channel blockers) Type Ia Ajmaline; Procainamide; Quinidine; Type Ib Lidocaine; Phenytoin; Type Ic Encainide; Flecainide; Propafenone; Type II (beta ...
Treat recurrent tachycardia associated with abnormal conduction pathways, such as Wolff–Parkinson–White syndrome; II Beta-blockers Atenolol; Bisoprolol; Carvedilol; Esmolol; Metoprolol; Nebivolol; Propranolol; Timolol; Beta blocker Propranolol also has some sodium channel-blocking effect. Decrease mortality in patients with myocardial ...
An antianginal is a drug used in the treatment of angina pectoris, a symptom of ischaemic heart disease.. Myocardial ischemia arises from the dysfunction of coronary macrovascular or microvascular components, leading to a compromised supply of oxygen and nutrients to the myocardium.
The metabolism of metoprolol can vary widely among patients, often as a result of hepatic impairment [9] or CYP2D6 polymorphism. [10] Metoprolol was first made in 1969, patented in 1970, and approved for medical use in 1978. [11] [12] [13] It is on the World Health Organization's List of Essential Medicines. [14] It is available as a generic ...
Labetalol was the first drug created that combined both α- and β-adrenergic receptor blocking properties. It was created to potentially fix the compensatory reflex issue that occurred when blocking a single receptor subtype, i.e. vasoconstriction after blocking β-adrenergic receptors or tachycardia after blocking α-adrenergic receptors.
The progress in β-blocker development led to the introduction of drugs with variety of properties. β-blockers were developed having a relative selectivity for cardiac β1-receptors (for example metoprolol and atenolol), partial adrenergic agonist activity , concomitant α-adrenergic blocking activity (for example labetalol and carvedilol) and ...
Antihypertensive agents comprise multiple classes of compounds that are intended to manage hypertension (high blood pressure). Antihypertensive therapy aims to maintain a blood pressure goal of <140/90 mmHg in all patients, as well as to prevent the progression or recurrence of cardiovascular diseases (CVD) in hypertensive patients with established CVD. [2]
Although α-methyldopa is generally regarded as a first-line agent, labetalol and metoprolol are also acceptable. Atenolol has been associated with intrauterine growth retardation, as well as decreased placental growth and weight when prescribed during pregnancy. ACEis and ARBs are contraindicated in women who are or who intend to become pregnant.